Use to diagnose patients for mucopolysaccharidosis type I (also known as MPS I, Hurler, Scheie, and Hurler-Scheie syndromes). To screen for all types of MPS, refer to Mucopolysaccharides Screen - Electrophoresis & Quantitation, Urine (0081352). To monitor glycosaminoglycans (GAGs) in patients previously diagnosed with MPS, refer to Mucopolysaccharides, Quantitative, Urine (0081357).
New York DOH Approval Status
Yellow (ACD Solution B), Lavender (K2EDTA), or Lavender (K3EDTA).
Transport 3 mL whole blood. (Min: 1 mL)
Room Temperature (Preferred) or Refrigerated
Grossly hemolyzed or heparinized specimens.
Additional information is required: Clinical Indication for testing.
Ambient: 3 days; Refrigerated: 3 days; Frozen: Unacceptable
12 - 65 nmol hydrolyzed/hr/mg protein
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2011416||Alpha-Iduronidase Activity, Leukocytes||24057-2|
|2011417||Alpha-Iduronidase, Leukocytes, Interp||48767-8|
- Mucopolysaccharidosis Type I